These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. Weisman MH. J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621 [Abstract] [Full Text] [Related]
6. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Isaacs JD. Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731 [Abstract] [Full Text] [Related]
14. Abatacept as add-on therapy for rheumatoid arthritis. Allison C. Issues Emerg Health Technol; 2005 Sep 24; (73):1-4. PubMed ID: 16317826 [Abstract] [Full Text] [Related]
15. Safety profile of abatacept in rheumatoid arthritis: a review. Khraishi M, Russell A, Olszynski WP. Clin Ther; 2010 Oct 24; 32(11):1855-70. PubMed ID: 21095481 [Abstract] [Full Text] [Related]
16. Use of biologics in rheumatoid arthritis: where are we going? Pucino F, Harbus PT, Goldbach-Mansky R. Am J Health Syst Pharm; 2006 Sep 15; 63(18 Suppl 4):S19-41. PubMed ID: 16960244 [Abstract] [Full Text] [Related]